Is Innova Captab overvalued or undervalued?

As of 14 August 2025, the valuation grade for Innova Captab has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 39.85, an EV to EBITDA ratio of 27.76, and a PEG ratio of 1.11. Compared to its peers, Innova Captab's valuation appears moderate; for instance, Sun Pharma has a PE ratio of 34.24 but is considered expensive, while Cipla is rated attractive with a PE of 23.41.
Innova Captab's recent performance shows a notable divergence from the Sensex, as it has returned -18.13% year-to-date, while the Sensex has gained 3.15%. This underperformance may suggest that the market is currently pricing in challenges or uncertainties that could impact future growth, reinforcing the view that the stock is fairly valued at this time.